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Background: Dexmedetomidine is a highly selective central α2-agonist with anesthetic and analgesic properties for
patients in intensive care units. There is little information about the relationship between dosage and plasma
concentration during long drug infusions of dexmedetomidine in critically ill patients, especially in Asians. In
addition, the administration of dexmedetomidine with a dosage of 0.2–0.7 μg/kg/h in Japan is different from that
with a dosage of 0.2–1.4 μg/kg/h in European countries and the USA. There has been concern about obtaining an
effective concentration with a small dosage and estimating the relationship between dosage and plasma
concentration. We conducted a prospective, observational, cohort study measuring plasma dexmedetomidine
concentrations.
Methods: Plasma dexmedetomidine concentrations of 67 samples from 34 patients in an intensive care unit for
2 months were measured by ultra performance liquid chromatography coupled with tandem mass spectrometry
using single-blind method, and the correlation coefficient between dosages and plasma concentrations was
estimated. Exclusion criteria included young patients (<16 years) and samples obtained from patients in which the
dosage of dexmedetomidine was changed within 3 h.
Results: Among the patients, 20 (58.8%) of the 34 received dexmedetomidine at 0.20–0.83 μg/kg/h, and in 40 of
the 67 samples for which dexmedetomidine had been administered, this occurred for a median duration of 18.5 h
(range, 3–87 h). The range of the dexmedetomidine plasma concentration was 0.22–2.50 ng/ml. By comparison
with other studies, with a dosage of 0.2–0.7 μg/kg/h, the patients in this setting could obtain an effective
dexmedetomidine concentration. The plasma dexmedetomidine concentration was moderately correlated with the
administered dosage (r = 0.653, P < 0.01). The approximate linear equation was y = 0.171x + 0.254. The range of
Richmond Agitation-Sedation Scale was 0 to −5.
Conclusions: We concluded that, with a dosage of 0.2–0.83 μg/kg/h, the patients in this setting could obtain an
effective dexmedetomidine concentration of 0.22–2.50 ng/ml. In addition, the plasma dexmedetomidine
concentration was moderately correlated with the administered dosage (r = 0.653, P < 0.01).
Trial registration: University Hospital Medical Information Network Clinical Trials Registry (UMIN-CTR)
UMIN000009115.
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Dexmedetomidine is a highly selective central α2-agonist
with anesthetic and analgesic properties for patients in in-
tensive care units (ICUs). In clinical settings, we adminis-
ter dexmedetomidine in intensive care units at a dosage of
0.2–0.7 μg/kg/h because there is no commercially available
blood concentration simulator. In Japan, a dosage of 0.2–
0.7 μg/kg/h was used because medical insurance approved
doses within this range. There is little information about
the relationship between dosage and plasma concentration
during long drug infusions of dexmedetomidine in critic-
ally ill patients [1,2]. In addition, adaptation to Asian pa-
tients using data on the dexmedetomidine dosage and
concentration from Caucasian patients may be a cause of
concern because of racial differences. The purpose of this
study was to confirm the effective dexmedetomidine con-
centration with a dosage of 0.2–0.7 μg/kg/h and to esti-
mate the correlation coefficient between dosages and
plasma concentrations in Japanese patients. We conducted
a prospective, observational, cohort study measuring
plasma dexmedetomidine in an intensive care unit by ultra
performance liquid chromatography coupled with tandem
mass spectrometry.
Methods
This study (UMIN number 000009115) was conducted in
the ICU of Nagoya City University Hospital, Japan. The
study protocol was approved by our institutional ethics
committee. Written informed consent was waived by the
institutional ethics committee because the study was per-
formed using residual blood (less than 1.0 ml) discarded
from blood gas analysis in the patients. However, before
analysis, we provided an oral description of the study and
obtained agreement, which was documented in the med-
ical record. This prospective, observational, cohort study
involved the recruitment of patients sequentially admitted
to the intensive care unit of Nagoya City University Hospital
for 2 months. All patients admitted to the ICU were eligible,
with the exception of patients less than 16 years old and pa-
tients in whom dosages of dexmedetomidine were changed
within 3 h. Patients with a history of intolerance to dexme-
detomidine or with significant metabolic, hematological, or
endocrine disease were excluded.
Patients received continuous infusion of dexmedeto-
midine (Precedex®, Hospira Japan, Osaka, Japan) at 0.2–
0.7 μg/kg/h without a loading dose. The dosage was ad-
ministered on the basis of clinical need and adjusted as
considered necessary to maintain optimal sedation. As
concomitant treatment, patients received the standard
care of the unit, which included administration of fen-
tanyl or epidural anesthesia with 0.125% levobupiva-
caine for pain relief and midazolam and propofol for
sedation. In the ICU, arterial blood gas analysis was per-
formed routinely at 5–7 a.m. Residual blood (less than1.0 ml) discarded from this blood gas analysis in the pa-
tients was used for this study. Arterial blood samples
(less than 1.0 ml) from all the patients in the ICU during
the survey period were collected in EDTA tubes imme-
diately. Samples were kept at 4°C and centrifuged.
Plasma was frozen at −80°C after separation and stored
until analysis.
Measurement of the concentration of dexmedetomi-
dine was performed using single-blind method. Arterial
blood samples were numbered without information
about the patients, even in terms of whether dexmedeto-
midine had been administered or not. In addition, these
samples labeled by number were sent for measurement,
and measurement was started without information about
the patients. An analytical assay for the determination of
dexmedetomidine was developed; the detailed descrip-
tion of which has been published previously [3]. Briefly,
the quantification of dexmedetomidine was carried out
using the original stable dexmedetomidine-d3 for elec-
trospray ionization-tandem mass spectrometry. Effica-
cious concentration levels (50 pg/ml to 5 ng/ml) could
be evaluated using a very small amount of plasma
(10 μl). The lower limit of quantification was 5 pg/ml in
the plasma.
Statistical analyses were performed with the computer
program Statistical Package for the Social Sciences (SPSS
19.0, Chicago, IL, USA). Power analysis was calculated for
the primary endpoint to estimate the correlation coeffi-
cient between dosages and plasma concentrations. We ob-
tained preliminary data and estimated the correlation
coefficient (r) to be approximately 0.5–0.6. A total sample
size of 25–38 was required to detect a correlation coeffi-
cient of 0.5–0.6 assuming two-tailed type I error of 5% and
type II error of 10%. Data are expressed as the mean ±
standard deviation, median (interquartile range) for non-
normally distributed variables (Kolmogorov-Smirnov test),
or number and percentage as appropriate. The correlation
between dosages and plasma concentrations of dexmede-
tomidine was determined by linear regression. Correlation
coefficient was calculated with Pearson's r or Spearman's ρ
by the type of distribution. All P values are two-tailed.
P values less than 0.01 were considered significant.
Results and discussion
Results
The characteristics of the patients are summarized in
Table 1. Among the patients, 20 (58.8%) of the 34 received
dexmedetomidine at 0.20–0.83 μg/kg/h, and in 40 samples
for which dexmedetomidine had been administered, this
occurred for a median duration of 18.5 h (range, 3–87 h).
The five patients who required dexmedetomidine infusion
for 87 h (more than 3.5 days) had three or four samples per
patient. For nine patients, multiple samples were obtained
(>1). The range of dexmedetomidine plasma concentration
Table 1 Characteristics of the patients
Characteristic Value
Number 20
Age (year) 67.5 (41.5, 75.5)
Male, female 14, 6
Height (cm) 162.4 ±9.7
Weight (kg) 56.9 ±12.1
Main reason for ICU admission, number (%)
Medical 7 (35 %)
Surgical 13 (65 %)
Values are mean ± SD or median (interquartile range) or number (%).
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dine concentration was moderately correlated with the ad-
ministered dosage (r = 0.653, P < 0.01; Figure 1). The
approximate linear equation was y = 0.171x + 0.259. The
range of Richmond Agitation-Sedation Scale was 0 to −5
(Table 2). With a small dosage of 0.2–0.7 μg/kg/h, the pa-
tients in this setting could obtain an effective dexmedeto-
midine concentration. We confirmed that a concentration
of 0 ng/ml dexmedetomidine was measured with the sam-
ples from the patients who were administered other seda-
tive drugs including midazolam, fentanyl, propofol, oral
diazepam, and oral clonidine hydrochloride without receiv-
ing dexmedetomidine.Table 2 Details of administered dexmedetomidine and
sedation
Drug treatment N = 40
Duration of infusion (h) 18.5 (10, 46.25) [range 3–87]
Plasma concentrations (ng/ml) 1.05 ± 0.56 [range 0.22–2.50]
Dosages (μg/kg/h) 0.41 (0.30, 0.58) [range 0.20–0.83]
Combined administration
No drug 14 (35 %)
1 drug 18 (45 %)
2 drugs 6 (15 %)
3 or more drugs 2 (5 %)
Fentanyl 23 (57.5 %)
Midazolam 3 (7.5 %)
Intubation 26 (65 %)
RASS
≧1 0 (0 %)
0 16 (40 %)
−1 5 (12.5 %)
−2 6 (15.0 %)
−3 6 (15.0 %)
−4 4 (10.0 %)
−5 3 (7.5 %)
Values are mean ± SD or median (interquartile range) or number (%).Discussion
Our study demonstrated that, at a small dosage of
0.2–0.83 μg/kg/h, the Japanese patients in this clinical
setting could obtain an effective dexmedetomidine
concentration of 0.22–2.50 ng/ml. We also found that
the plasma dexmedetomidine concentration was mod-
erately correlated with the administered dosage. We
thought that this information might be useful in a
clinical setting for Japanese patients.
The effective sedative concentration of dexmedetomi-
dine was thought to be between 0.2 and 3.2 ng/ml in
previous studies. Ebert et al. described in detail the esti-
mation of sedative effect and cold pressor test with sev-
eral concentrations in ten healthy men (20–27 years old)
[4]. In their study, recall and recognition decreased at a
dose of more than 0.7 ng/ml. Pain response to the cold
pressor test decreased at more than 3.2 ng/ml. This re-
sult suggests that a decrease of pain response might re-
quire more than 3.2 ng/ml; however, suppression of
recognition might occur at 0.7 ng/ml. Despite not dir-
ectly measuring dexmedetomidine concentration, Hall
et al. reported sedative properties of a small dose of dex-
medetomidine [5]. In their study, seven healthy volun-
teers received 0.2 or 0.6 μg/kg/h dexmedetomidine after
a 10-min initial dose of 6 μg/kg/h. In this study, only
0.2 μg/kg/h dexmedetomidine suppressed the visual ana-
log scale of pain. According to these papers, our dexme-
detomidine range of 0.22–2.50 ng/ml might be within
the effective sedative concentration.
At a dosage of 0.2–0.83 μg/kg/h, the Japanese patients
in this clinical setting could obtain an effective dexmede-
tomidine concentration of 0.22–2.50 ng/ml; this data
might be informative for Asian people. Adaptation to
Asian patients using the data on dexmedetomidine dos-
age and concentration from Caucasian patients remains
a cause of concern because of racial differences. These
racial differences consist of not only differences in phys-
ique between Asians and Caucasians but also disparities
in pain [6,7]. Konstantatos et al. investigated the rela-
tionship between race and early opioid consumption.
In this paper, they described that Chinese patients in
Hong Kong required less opioid and experienced greater
pain intensity and pruritus than Caucasian patients [6].
However, in our study at a range of 0.22–2.50 ng/ml, we
could obtain an effective sedation level because the range
of Richmond Agitation-Sedation Scale was 0 to −5. Our
data demonstrated that the Japanese effective concentra-
tion range of dexmedetomidine might be almost equal to
that of Caucasians.
The pharmacokinetics of dexmedetomidine in healthy
volunteers [4,5,8,9] might differ from that in intensive care
patients [1,2]. There is little information on its pharmaco-
kinetics after long-term (>48 h) infusion in an intensive
care unit setting [2]. Our samples were obtained in an
Figure 1 The correlation coefficient between dosages and plasma concentrations. The white circles and strait line indicated the result of
each sample and the linear equation, respectively. The plasma dexmedetomidine concentration was moderately correlated with the administered
dosage (r = 0.653, P < 0.01). The approximate linear equation was y = 0.171x + 0.259.
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(range, 3–87 h). Our data might be useful and informative
for long-term sedation, especially in Asians.
In this study, we administered continuous infusion of
dexmedetomidine without a loading dose because many
patients had already received other analgesic and seda-
tive drugs, and we wanted to avoid abrupt hemodynamic
effects [4] with a loading dose. In terms of the pharma-
codynamic effect, the plasma concentration might vary
because of the difference of infusion duration prior to
blood sampling, even at a constant administration rate
of dexmedetomidine. This study was an observational
study, so we measured the blood samples in a clinical
setting. In addition, we adopted the samples after con-
tinuous administration for more than 3 h because we
could confirm an effect of administration of dexmedeto-
midine within 2–3 h after continuous administration in
a clinical setting. With a loading dose, the correlation of
the plasma dexmedetomidine concentration might be
stronger with the administered dosage.
Our study had several other limitations. First, the num-
ber of patients was small, and the patient characteristics
varied. Because this study was observational, as concomi-
tant treatment, patients received the standard care of the
unit, which included other pain relief and sedation drugs,
such as the administration of fentanyl, epidural anesthesia,
midazolam, and propofol. In future studies, by selectingpatients undergoing a certain type of surgery, by control-
ling other pain relief and sedation drugs, as well as using
estimated pain, we may be able to obtain more precise data
concerning the strategy for administering dexmedetomi-
dine. Second, we could not completely rule out that the
measurement had been affected by the other drugs. We
confirmed that a dexmedetomidine concentration of 0 ng/ml
was measured in the samples from the patients who
had been administered other sedative drugs including mid-
azolam, fentanyl, propofol, oral diazepam, and oral cloni-
dine hydrochloride without receiving dexmedetomidine.
However, these findings could not guarantee that our
method of measuring the dexmedetomidine concentration
was unaffected by these other drugs. This might be consid-
ered a typical limitation in a clinical setting. Third, the five
patients who required dexmedetomidine infusion for 87 h
(more than 3.5 days) had three or four samples per patient.
In total, multiple samples were obtained from nine patients
(>1). Therefore, we could not rule out that these multiple
samples might have induced variation in findings for all
the patients.
Conclusions
In conclusion, we demonstrated that, at a dosage of
0.2–0.83 μg/kg/h, the Japanese patients in this clinical
setting could obtain an effective dexmedetomidine con-
centration of 0.22–2.50 ng/ml. In addition, the plasma
Fujita et al. Journal of Intensive Care 2013, 1:15 Page 5 of 5
http://www.jintensivecare.com/content/1/1/15dexmedetomidine concentration was moderately corre-
lated with the administered dosage (r = 0.653, P < 0.01).
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